GE HealthCare, Siemens Push AI Perfusion Imaging to $7.89 Billion
GE HealthCare, Siemens Push AI Perfusion Imaging to $7.89 Billion
AI-driven predictive analytics, portable ECMO device launches, and a $2.8 billion North American installed base are positioning perfusion radiology as the diagnostic imaging sector’s fastest-maturing clinical intelligence platform across neurology, cardiology, and oncology.
The global perfusion radiology market, valued at USD 4.25 billion in 2024, is advancing as GE HealthCare, Siemens Healthineers, and Philips converge on AI-integrated perfusion analytics and institutional partnerships as core differentiators. Parallel advances in portable ECMO, predictive AI perfusion management, and 3D-printed vascular tissue are expanding applications into ICUs, transplantation, and telemedicine networks. Maximize Market Research forecasts USD 7.89 billion by 2032 at an 8.4% CAGR, with North America holding a USD 2.8 billion base.
GE HealthCare and Siemens Healthineers Deploy AI Analytics Across CT and MRI Perfusion Platforms
GE HealthCare and Siemens Healthineers are advancing AI/ML integration across CT and MRI perfusion platforms, enabling real-time parameter monitoring, automated anomaly detection, and outcome forecasting for stroke, ischemia, and cardiovascular care. CT perfusion retains the largest share due to accessibility and cost efficiency, while MRI perfusion is gaining traction in 2025–2026 for superior soft-tissue contrast in neurology and oncology. Both firms are formalizing institution partnerships to align product development with clinical workflows, accelerating adoption across hospitals, diagnostics, and research settings, per Maximize Market Research.
“GE HealthCare and Siemens Healthineers embedding AI into perfusion analytics is not incremental — it is the platform transition that converts perfusion imaging from a static snapshot into a continuous clinical intelligence stream. That shift redefines its value in stroke protocols, cardiac surgery planning, and oncology staging simultaneously.”
Philips and Abbott Advance Portable Perfusion Devices and Cardiovascular Applications as Organ Transplant Segment Expands
Philips and Abbott Laboratories are prioritizing portable, miniaturized perfusion platforms, including next-generation ECMO systems for transport and extended support. This targets the cardiovascular segment, driven by high heart disease prevalence. Abbott, via St. Jude Medical and Thoratec, is expanding into ventricular assist devices, while machine perfusion advances accelerate organ transplantation across North America and Europe.
“Portable ECMO systems that function outside the ICU are a logistics revolution for cardiac care. When you can maintain perfusion quality during inter-facility transport, you expand the catchment area for advanced cardiac intervention — and that directly expands the addressable patient population for every platform manufacturer in this market.”
Market Context: $4.25 Billion Base, North America’s $2.8 Billion Lead, and Asia-Pacific’s Rapid Ascent
Maximize Maximize Market Research values the global perfusion radiology market at USD 4.25 billion in 2024, projected to reach USD 7.89 billion by 2032 at an 8.4% CAGR. North America leads with ~USD 2.8 billion, supported by advanced infrastructure and the presence of GE HealthCare, Siemens Healthineers, Abbott Laboratories, and Boston Scientific. Europe ranks second, while Asia-Pacific is fastest-growing on rising cardiovascular and stroke incidence. High equipment costs and operational complexity remain key adoption barriers in emerging healthcare systems.